Functional Links Between Aβ Toxicity, Endocytic Trafficking, and Alzheimer's Disease Risk Factors in Yeast

Sebastian Treusch,[1,2] Shusei Hamamichi,[1,3] Jessica L. Goodman,[1] Kent E.S. Matlack,[1,2] Chee Yeun Chung,[1] Valeriya Baru,[1,2] Joshua M. Shulman,[4,5] Antonio Parrado,[6] Brooke J. Bevis,[1] Julie S. Valastyan,[1,2] Haesun Han,[1] Malin Lindhagen-Persson,[7] Eric M. Reiman,[8,9] Denis A. Evans,[10] David A. Bennett,[11] Anders Olofsson,[7] Philip L. DeJager,[4,5] Rudolph E. Tanzi,[6] Kim A. Caldwell,[3] Guy A. Caldwell,[3] Susan Lindquist[1,2*]

[1]Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA. [2]Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. [3]Department of Biological Sciences, The University of Alabama, Tuscaloosa, AL 35487, USA. [4]Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. [5]Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA. [6]Genetics and Aging Research Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. [7]Department of Medical Biochemistry and Biophysics, Umea University, Umea, Sweden. [8]Neurogenomics Division, Translational Genomics Research Institute and Arizona Alzheimer's Consortium, Phoenix, AZ 85004, USA. [9]Banner Alzheimer's Institute and Department of Psychiatry, University of Arizona, Phoenix, AZ 85006, USA. [10]Rush Institute for Healthy Aging, Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA. [11]Rush Alzheimer's Disease Center, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.

*To whom correspondence should be addressed. E-mail: lindquist_admin@wi.mit.edu

Aβ (amyloid beta peptide) is an important contributor to Alzheimer's disease (AD). We modeled Aβ toxicity in yeast by directing the peptide to the secretory pathway. A genome-wide screen for toxicity modifiers identified the yeast homolog of phosphatidylinositol binding clathrin assembly protein (*PICALM*) and other endocytic factors connected to AD whose relationship to Aβ was previously unknown. The factors identified in yeast modified Aβ toxicity in glutamatergic neurons of *Caenorhabditis elegans* and in primary rat cortical neurons. In yeast, Aβ impaired the endocytic trafficking of a plasma membrane receptor, which was ameliorated by endocytic pathway factors identified in the yeast screen. Thus, links between Aβ, endocytosis, and human AD risk factors can be ascertained using yeast as a model system.

Yeast cells lack the specialized processes of neuronal cells and the cell-cell communications that modulate neuropathology. However, the most fundamental features of eukaryotic cell biology evolved before the split between yeast and metazoans. Yeast studies of the cell cycle, DNA damage repair and checkpoints produced pivotal advances in cancer biology (*1*). More recently, the conservation of protein-homeostasis networks, vesicular trafficking, mitochondrial biology, autophagy, and apoptosis facilitated the development of yeast models for protein-misfolding pathologies (*1*). When human diseases impinge on common features of eukaryotic cell biology, yeast's unequaled toolkit offers an attractive discovery platform, as established for multiple aspects of α-synuclein toxicity (*2–7*).

Here, we wanted to create a yeast model of cellular toxicities elicited by the amyloid β (Aβ) peptide. According to the still hotly debated "amyloid cascade" hypothesis, Aβ is causal in both sporadic and familial Alzheimer's Disease (AD) (*8*). The oligomeric forms of the peptide appear to be the most toxic (*9–12*). Similar toxic oligomers, formed by unrelated proteins but all recognized by the same conformation-specific antibody, are associated with other neurodegenerative diseases and with yeast prions (*13*, *14*). Thus, the toxicity of such oligomers is an ancient protein-folding problem.

In addition to Aβ, neurofibrillary tangles (NFTs) of tau, a microtubule-binding protein, are hallmarks of AD pathology (*15*). Aβ seems to act upstream of tau (*16*, *17*). Genetic AD risk factors are now being identified through genome-wide association studies (GWAS), but their relationship to Aβ is unknown.

A yeast model of Aβ toxicity. The most toxic form of Aβ, Aβ 1-42, is generated by proteolytic cleavage of APP, the transmembrane amyloid precursor protein (*18*, *19*). APP processing occurs in the secretory pathway, which releases Aβ into the trans-Golgi, endosomal compartments, and extracellular space. Aβ then interacts with the plasma membrane and is subject to endocytosis and further vesicular trafficking (*18*). To recapitulate this multi-compartment trafficking in yeast, we fused an ER targeting signal to the N-terminus of Aβ 1-42 (referred to as ssAβ 1-42, Fig. 1A). Without an ER retention signal, after cleavage of the signal sequence Aβ 1-42 should simply transit through the secretory

pathway to the plasma membrane (*20*). The yeast cell wall will restrain secreted peptides from diffusing into the culture medium, allowing Aβ to interact with the plasma membrane, undergo endocytosis, and thereby transit through endocytic compartments potentially relevant to AD (fig. S1A).

When expressed from a galactose-inducible (*GAL1*) promoter and a multi-copy plasmid, ssAβ 1-42 decreased cell growth (Fig. 1A). Using the same plasmid, Aβ 1-40 was less toxic, as were Pdi1 (an ER resident protein), BPTI (a small protein commonly used to study secretion), and even BPTI[C51A] (a variant that misfolds in the ER (*21*)) (Fig. 1A).

For genetic screens, strains with uniform stable ssAβ 1-42 expression were constructed by integrating tandem copies in the genome (fig. S1B). We targeted a locus where insertions have no deleterious consequences and selected strains that grew slowly upon galactose induction, but with no major increase in lethality (fig. S1C and table S1). The peptide produced was of the expected size for processed Aβ (fig. S1D), verified by mass spectrometry (fig. S1E). Localization to secretory compartments was confirmed by immunofluorescence (Fig. 1B).

When lysates were not subjected to boiling, which disrupts oligomeric species, we detected Aβ oligomers on Bis-Tris gels (fig. S1D). These forms reacted more strongly with the antibody NAB61, which preferentially recognizes toxic Aβ oligomers in AD patients (Fig. 1C) (*10*). These species disappeared upon boiling in lithium dodecyl sulfate (LDS) buffer. Assaying lysates by size-exclusion chromatography with a monoclonal IgM anti-Aβ antibody specific for Aβ oligomers detected a broad range of oligomeric species (Fig. 1D and fig. S1F) (*22*). Eliminating preparation artifacts, these were not seen when purified monomeric Aβ peptide was added to control cultures prior to lysis (Fig. 1D). In strains that produced the same levels of Aβ 1-40 and 1-42 monomer after boiling (fig. S1G), oligomers were much more abundant for Aβ 1-42 prior to boiling (Fig. 1E). Thus, oligomeric Aβ forms contribute to toxicity in yeast, as in neurons.

Screen for genetic modifiers of Aβ toxicity. We transformed a screening strain with an overexpression library of 5532 full length open reading frames (ORFs) (~90% of yeast ORFs) under control of the same promoter used for ssAβ 1-42 (fig. S2A). Individual transformants were arrayed in media that prevented induction of either ssAβ 1-42 or the library constructs, then plated (four replicates each) onto several types of inducing media, chosen to support different levels of mitochondrial respiration (fig. S2B; (*23*), table S2). Intermediate levels of Aβ toxicity enabled the identification of enhancers and suppressors in the same screen (fig. S1B; (*23*), table S2). Genes that decreased or increased growth (fig. S2B) were retested in an independently derived screening strain. Secondary screens eliminated genes that simply altered

expression of Aβ from the *GAL1* promoter (fig. S3) or growth in the absence of Aβ.

We identified 23 suppressors and 17 enhancers (table S2). Only a few modifiers were strongly affected by the state of respiration (table S2). The screen hits comprised a wide range of cellular functions. Numerous hits had sequence similarity to human genes, and twelve had very clear human homologs (determined by HomoloGene or by analogous functionality [*SLA1 – SH3KBP1*] (*24*)) (Table 1). We focused further analysis on these.

Three of these twelve genes had functions related to clathrin-mediated endocytosis (*YAP1802*, *INP52* & *SLA1*; *P*=3.89e-4) and seven were functionally associated with the cytoskeleton (*YAP1802*, *INP52, SLA1*, *CRM1, GRR1, KEM1* & *RTS1*; *P*=6.06e-8). None were identified in our previous screen for modifiers of α-syn toxicity (*5*, *7*), establishing their specificity for the type of toxicity caused by Aβ 1-42.

Modifiers of Aβ toxicity are associated with AD susceptibility. Several human homologs of our yeast hits had connections to human AD risk factors, particularly those involved in clathrin-mediated endocytosis (Table 1). The human homolog of yeast *YAP1802*, *PICALM*, is one of the most highly confirmed risk factors for sporadic AD (*25*, *26*). Another AD risk factor, *BIN1,* is involved in synaptic vesicle endocytosis and is believed to interact with synaptojanin, the human homolog of yeast *INP52* (*27*). The functional homolog of yeast *SLA1, SH3KBP1* (*28*), directly interacts with the risk factor *CD2AP* (*29*, *30*). *CD2AP* links endocytosis to cytoskeletal dynamics and our other major class of screen hits.

To assess the potential clinical relevance of other screen hits with highly conserved human homologs we examined association with AD susceptibility using data from a published family-based GWAS (*31*, *32*). Using a family-based association test, we discovered a suggestive association of *XPO1* (*CRM1* homolog, rs6545886, *P*=0.003) with AD susceptibility ((*23*), table S3).

Next, we leveraged genotyping with extensive clinical and pathological data from two large epidemiological studies of aging, cognition, and AD (*33*, *34*) ((*23*), table S4-7). Using a quantitative summary measure of global AD pathologic burden available in these cohorts, counting both amyloid plaques and NFTs, we found that two additional loci identified by our yeast screen, *ADSSL1* (*ADE12* homolog, rs1128880, *P*=0.001) and *RABGEF1* (*VPS9* homolog, rs17566701, *P*=0.002) showed evidence of association with AD neuropathology (table S7). Both loci also harbored suggestive association signals with episodic memory decline (table S6). Thus, our yeast screen connects multiple human AD risk factors, and suggested risk factors, to Aβ toxicity.

***C. elegans* model of Aβ toxicity.** To directly test our modifiers for effects on Aβ toxicity in neurons, we created a

transgenic *C. elegans* model that expressed Aβ 1-42 in glutamatergic neurons, a neuronal subtype particularly vulnerable in AD. (A previous model expressed Aβ in body-wall muscles (*35*).) We used the *eat-4* promoter, which regulates the BNPI glutamate transporter and, again, targeted Aβ to the secretory pathway (*35*). The Aβ transgene was integrated into chromosomal DNA to ensure the same Aβ 1-42 expression levels in all animals.

C. elegans has highly stereotyped cell lineages. Wild-type worms invariably have five glutamatergic neurons in their tails, which we visualized with *eat-4*-regulated GFP. Crossing worms expressing ssAβ to worms carrying this reporter resulted in the loss of GFP-marked glutamatergic neurons in an age-related manner: at day three only 48% of worms had five intact glutamatergic neurons, and at day seven only 25% did (Fig. 2A).

To test the effects of our screen hits (Table 1) we established three independent transgenic worm lines for each gene, again expressing the protein from the *eat-4* promoter. Unrelated control proteins mCherry and LacZ had no effect on Aβ toxicity. All three *C. elegans* homologs of the genes involved in clathrin-mediated endocytosis, *unc-11*, *unc-26*, and *Y44E3A.4*, increased the percentage of worms with five intact glutamatergic neurons (Fig. 2).

Finally, we tested four hits, three suppressors and one enhancer, involved in a diverse array of pathways. The yeast *RTS1* gene encodes a phosphatase regulatory subunit that controls several stress-response pathways. The *ADE12* gene product catalyzes the first step in the synthesis of adenosine monophosphate from inosine 5-monophosphate. The *C. elegans* homologs of each gene suppressed the Aβ-induced loss of glutamatergic neurons (Fig. 2A). We were unable to clone the worm homologs of *GRR1, VPS9,* or *CRM1*. However, *CRM1* encodes a highly conserved nuclear export receptor. Expression of *CRM1*'s human homologue, *XPO1,* protected nematode glutamatergic neurons from Aβ (Fig. 2A). *PBS2/MAP2K4,* a MAP kinase involved in stress responses, increased neuronal loss (Fig. 2).

The effect of each gene was statistically significant ($p < 0.05$) for both the modest neuronal toxicity evinced at three days and the more severe toxicity at seven days. Importantly, the modifiers did not alter the levels of Aβ mRNA, which we tested by semi-quantitative RT-PCR (fig. S5). Thus, every gene we tested in *C. elegans* glutamatergic neurons modified Aβ toxicity in the same direction (suppression vs. enhancement) as they did in yeast.

PICALM suppresses the toxicity of soluble Aβ oligomers with rat cortical neurons. *PICALM* is one of the most highly validated AD risk factors and its efficacy in our yeast and nematode models strongly suggests it alters Aβ toxicity. Modeling this in cultured mammalian neurons is not trivial, because any Aβ peptide expressed in the secretory

pathway would simply diffuse away from the cell. Exogenously applied, pre-formed oligomeric Aβ species are often employed to model toxicity (*13*, *36*), but their relevance is highly debated. We reasoned that a positive result for the highly validated AD risk factor *PICALM* might not only validate this assay but confirm the role of *PICALM* in Aβ detoxification.

We analyzed cortical neurons, a neuronal population particularly relevant to AD. Embryos from female rats with timed pregnancies were harvested at 18 days of gestation. Cortices dissected from these embryos were dissociated, plated and cultured for up to 21 days (*23*). The production of toxic Aβ oligomers is notoriously variable. We prepared oligomers according to several published methods, characterized them biochemically, and tested them for producing consistent levels of toxicity in our cortical neuronal preparations (Fig. 3, fig. S6 and fig. S7). The loss of toxicity when the same samples were allowed to form Aβ fibers (fig. S6A and S6C) confirmed the importance of the oligomeric species (fig. S6D).

Next, we infected neurons with lentiviruses engineered to express GFP or *PICALM*. When Aβ oligomers were added to these neurons, GFP had no effect but *PICALM* partially rescued the cells from Aβ induced cell death in a dose-dependent manner (Fig. 3). Rescue was significant whether assayed by cellular ATP levels (Fig. 3A) or by counting the number of MAP2 positive neurons (Fig. 3B and Fig. 3C). As previously described for midbrain neurons (*7*), we found that *RAB1* protected cortical neurons from α-syn toxicity when this protein was expressed intracellularly by viral transfection. However, *RAB1* was ineffective against Aβ oligomers, confirming the specificity of *PICALM* for the type of toxicity caused by Aβ oligomers (fig. S7).

Effect of Aβ on endocytosis and trafficking. The role of *PICALM* in AD is unknown, but it has been postulated to affect disease by modifying APP trafficking (*25*). However, our experiments in yeast, nematode and rat neurons clearly establish *PICALM* as a modifier of Aβ toxicity itself. To investigate the mechanism for *PICALM* and the other modifiers that affect clathrin-mediated endocytosis, we returned to yeast.

One possibility is that clathrin-mediated endocytosis modulates Aβ toxicity simply by shunting toxic Aβ species to the lysosomal/vacuolar system for degradation. However, immunoblotting of yeast lysates indicated these modifiers had little effect on Aβ levels (fig. S4). Alternatively, if Aβ specifically perturbs endocytic homeostasis, up-regulation of this pathway might ameliorate the defect.

To determine if Aβ altered clathrin distributions, we used a strain in which endogenous clathrin light chain (Clc1) was tagged with GFP, a fully functional fusion. A control strain exhibited the expected distribution of Clc1-GFP foci (*37*). Aβ

perturbed clathrin localization, increasing both the number and brightness of foci, but decreasing their average size (Fig. 4A).

Such a pattern might indicate a defect in clathrin-mediated secretion as well as in endocytosis. To test effects of Aβ on secretion, we used a halo assay for secretion of the α-factor mating pheromone. As a control, we also tested the effects of α-syn expression, which produces a strong defect in secretion (*7*) (Fig. 4B). Unlike α-syn, Aβ did not inhibit secretion (Fig. 4B).

To assess the impact of Aβ on clathrin-mediated endocytosis specifically, we examined the well-characterized substrate Ste3, a member of the highly conserved G-protein coupled receptor family. Ste3 is targeted to the plasma membrane. In the absence of its ligand, the yeast mating-factor, it is constitutively endocytosed and degraded in the vacuole (*38*). As expected, a Ste3-YFP fusion was primarily localized to the vacuole in a control strain (Fig. 4C). In Aβ-expressing strains, endocytic trafficking of Ste3-YFP was profoundly perturbed and the protein was localized to numerous foci ((*23*), Fig. 4C). Aβ expression resulted in a reduction of vacuolar organelle size without a disruption in morphology, consistent with reduced delivery of cargo to this organelle. Finally, we tested the effects of the three Aβ toxicity suppressors that function in endocytic trafficking, *YAP1802*, *INP52*, and *SLA1*. Each partially reversed the defect in Ste3-YFP trafficking (Fig. 4C).

Conclusions and perspectives. Our yeast model allowed us to conduct an unbiased screen of an entire genome for modifiers of Aβ toxicity. The emergence of three different genes involved in the process of clathrin-mediated endocytosis from nearly 6,000 tested ORFs confirms that the Aβ peptide in our model is trafficking through the secretory compartments as expected. More importantly, the ability of endocytic genes to rescue Aβ toxicity, together with the effects of Aβ on clathrin localization and the trafficking of a G protein-coupled receptor, establish that within these highly diverse organisms clathrin-mediated endocytosis is a critical point of vulnerability to Aβ.

Aβ oligomers have been reported to increase endocytosis in cultured cells (*39*), and human-induced neuronal cells derived from the fibroblasts of AD patients exhibit defects in endocytosis (*40*). Mechanistically, in our Aβ-expressing cells, the increased number of clathrin foci, the internalized foci of Ste3, and the effects of genetic modifiers on vacuolar localization all suggest that Aβ affects this pathway by interfering with the ability of endocytosed transmembrane receptors to reach their proper destinations. *PICALM*, as well as two genes whose protein products (*BIN1* and *CD2AP*) interact with hits from our screen are AD risk factors. Given the diversity of pathologies however, their connection to Aβ toxicity was unknown. Our work in yeast, nematodes, and rat cortical neurons clearly places these factors within the Aβ cascade, linking Aβ to the genetics of sporadic AD.

Neurons are particularly vulnerable to perturbations in the homeostasis of endocytosis, because they must constantly recycle both neurotransmitters and their receptors (*41*). Aβ interacts with, and alters signaling by, a variety of neuronal receptors (*42*). We propose that the conformational flexibility of these oligomers allows them to interact rather promiscuously with conformationally flexible unliganded receptors, which, in turn, disrupts endocytic homeostasis.

Our yeast screen also identified seven conserved genes functionally associated with the cytoskeleton. Because yeasts do not express tau, our findings may indicate that the connection between Aβ toxicity and the cytoskeleton is more deeply rooted than tau alone, probably involving clathrin-mediated endocytosis. In analyzing human GWAS data we also uncovered suggestive associations between AD and three other genes, *XPO1*, *ADSSL1*, and *RABGEF1*, and confirmed their Aβ relationships in yeast and nematode.

The treatments available for AD are few and their efficacy limited. Determining how best to rescue neuronal function in the context of the whole brain is a problem of staggering proportions. Our yeast model provides a tool for identifying genetic leads, investigating their mechanisms of action, and screening for genetic and small molecule modifiers of this devastating and etiologically complex disease.

References and Notes

1. V. Khurana, S. Lindquist, Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? *Nat Rev Neurosci* **11**, 436 (2010).
2. T. F. Outeiro, S. Lindquist, Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science* **302**, 1772 (2003).
3. N. Thayanidhi *et al.*, Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. *Mol Biol Cell* **21**, 1850 (2010).
4. A. R. Winslow *et al.*, alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. *J Cell Biol* **190**, 1023 (2010).
5. A. D. Gitler *et al.*, Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. *Nat Genet* **41**, 308 (2009).
6. L. J. Su *et al.*, Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. *Dis Model Mech* **3**, 194 (2009).
7. A. A. Cooper *et al.*, Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Science* **313**, 324 (2006).

8. J. Hardy, D. J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**, 353 (2002).

9. M. Knobloch, U. Konietzko, D. C. Krebs, R. M. Nitsch, Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. *Neurobiol Aging* **28**, 1297 (2007).

10. E. B. Lee *et al.*, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. *J Biol Chem* **281**, 4292 (2006).

11. G. M. Shankar *et al.*, Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* **14**, 837 (2008).

12. D. M. Walsh, B. P. Tseng, R. E. Rydel, M. B. Podlisny, D. J. Selkoe, The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. *Biochemistry* **39**, 10831 (2000).

13. R. Kayed *et al.*, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* **300**, 486 (2003).

14. J. Shorter, S. Lindquist, Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. *Science* **304**, 1793 (2004).

15. F. M. LaFerla, Pathways linking Abeta and tau pathologies. *Biochem Soc Trans* **38**, 993 (2010).

16. L. M. Ittner *et al.*, Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell* **142**, 387 (2010).

17. E. D. Roberson *et al.*, Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* **316**, 750 (2007).

18. G. Thinakaran, E. H. Koo, Amyloid precursor protein trafficking, processing, and function. *J Biol Chem* **283**, 29615 (2008).

19. D. J. Selkoe, M. S. Wolfe, Presenilin: running with scissors in the membrane. *Cell* **131**, 215 (2007).

20. H. R. Pelham, Control of protein exit from the endoplasmic reticulum. *Annu Rev Cell Biol* **5**, 1 (1989).

21. J. M. Kowalski, R. N. Parekh, K. D. Wittrup, Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. *Biochemistry* **37**, 1264 (1998).

22. M. Lindhagen-Persson, K. Brannstrom, M. Vestling, M. Steinitz, A. Olofsson, Amyloid-beta oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies. *PLoS One* **5**, e13928 (2010).

23. Please refer to Supporting Online Material.

24. S. D. Stamenova, R. Dunn, A. S. Adler, L. Hicke, The Rsp5 ubiquitin ligase binds to and ubiquitinates members of the yeast CIN85-endophilin complex, Sla1-Rvs167. *J Biol Chem* **279**, 16017 (2004).

25. D. Harold *et al.*, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* **41**, 1088 (2009).

26. J. C. Lambert *et al.*, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* **41**, 1094 (2009).

27. A. R. Ramjaun, K. D. Micheva, I. Bouchelet, P. S. McPherson, Identification and characterization of a nerve terminal-enriched amphiphysin isoform. *J Biol Chem* **272**, 16700 (1997).

28. G. Gaidos, S. Soni, D. J. Oswald, P. A. Toselli, K. H. Kirsch, Structure and function analysis of the CMS/CIN85 protein family identifies actin-bundling properties and heterotypic-complex formation. *J Cell Sci* **120**, 2366 (2007).

29. P. Hollingworth *et al.*, Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* **43**, 429 (2011).

30. A. C. Naj *et al.*, Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* **43**, 436 (2011).

31. L. Bertram *et al.*, Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet* **83**, 623 (2008).

32. D. Blacker *et al.*, ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. *Neurology* **48**, 139 (1997).

33. D. A. Bennett, P. L. De Jager, S. E. Leurgans, J. A. Schneider, Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. *Neurology* **72**, 1495 (2009).

34. J. M. Shulman *et al.*, Intermediate phenotypes identify divergent pathways to Alzheimer's disease. *PLoS ONE* **5**, e1124 (2010).

35. C. D. Link, Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. *Proc Natl Acad Sci U S A* **92**, 9368 (1995).

36. D. Bozyczko-Coyne *et al.*, CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. *J Neurochem* **77**, 849 (2001).

37. Y. Sun, S. Carroll, M. Kaksonen, J. Y. Toshima, D. G. Drubin, PtdIns(4,5)P2 turnover is required for multiple stages during clathrin- and actin-dependent endocytic internalization. *J Cell Biol* **177**, 355 (2007).

38. L. Maldonado-Baez *et al.*, Interaction between Epsin/Yap180 adaptors and the scaffolds Ede1/Pan1 is required for endocytosis. *Mol Biol Cell* **19**, 2936 (2008).

39. A. J. Minano-Molina *et al.*, Soluble Oligomers of Amyloid-{beta} Peptide Disrupt Membrane Trafficking of {alpha}-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Contributing to Early Synapse Dysfunction. *J Biol Chem* **286**, 27311 (2011).

40. L. Qiang *et al.*, Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. *Cell* **146**, 359 (2011).

41. N. Jung, V. Haucke, Clathrin-mediated endocytosis at synapses. *Traffic* **8**, 1129 (2007).

42. Y. Verdier, M. Zarandi, B. Penke, Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. *J Pept Sci* **10**, 229 (2004).

Supporting Online Material
www.sciencemag.org/cgi/content/full/science.1213210/DC1
Materials and Methods
Figs. S1 to S7
Tables S1 to S7
References (*43–56*)

26 August 2011; accepted 18 October 2011
Published online 27 October 2011; 10.1126/science.1213210

Table 1. Genes that modify Aβ toxicity. Yeast genes with clear nematode and human homologs were identified in an unbiased screen of 5,532 single copy plasmids carrying yeast ORFs under the control of the *GAL1* promoter in three independent screens in three inducing medias (*23*).

Yeast Aβ Suppressors	Cellular Function	*C. elegans* Homolog	Human Homolog	Connection of human homologs to AD Risk
YAP1802	Endocytosis	unc-11*	PICALM	Validated risk factor[1,2]
INP52	Endocytosis	unc-26*	SYNJ1	Interacts with validated risk factor BIN1 (*27*)
SLA1	Endocytosis	Y44E3A.4*	SH3KBP1	Interacts with validated risk factor CD2AP (*28*)
RTS1	Phosphatase regulation	pptr-2*	PPP2R5C	
ADE12	Adenylosuccinate synthesis	C37H5.6b*	ADSSL1	Potential risk factor, this study[3]
CRM1	Nuclear protein export	xpo-1*	XPO1	Potential risk factor, this study[2]
GRR1	Ubiquitination	C02F5.7	FBXL2	
VPS9	Vesicle transport	rabx-5	RABGEF1	Potential risk factor, this study[3]
Yeast Aβ Enhancers				
PBS2	Osmotic stress response	mkk-4*	MAP2K4	Activated by Aβ oligomers in cortical neurons (*36*)
KEM1	RNA processing	xrn-1	XRN1	
MVP1	Vacuolar sorting	lst-4	SNX8	
PMT2	Mannosylation	-	POMT2	

* Genes tested in the *C. elegans* model

[1]Table S3

[2]Table S6

[3]Table S7

Fig. 1. Expression of Aβ in the yeast secretory pathway. (**A**) Comparison of ssAβ 1-42 toxicity with ssAβ 1-40, ssBPTI (WT and C51A) and Pdi1. Proteins were expressed using the inducible *GAL1* promoter and a high copy number plasmid. Strains carrying the plasmids were serially diluted and spotted on inducing (galactose) and non-inducing (glucose) media. (**B**) Immunostaining for ssAβ 1-42 reveals localization to the ER/secretory pathway. Aβ was detected in the ER (ring surrounding the nucleus, stained blue with DAPI) and in small foci throughout the cell. The scale bar is 5μm. All figures are on the same scale. (**C**) Immunoblot with NAB61, an antibody specific for soluble Aβ oligomers, detects oligomers in unboiled samples. An immunoblot with the 6E10 Aβ-specific antibody is shown for reference. (**D**) An indirect ELISA assay using a monoclonal Aβ oligomer-specific antibody detects Aβ oligomers in the 1 x ssAβ strain and, more so, in the two screening strains (n=5; error bars to small to be visible; **: $p<0.01$, based on Dunnett's test). (**E**) Aβ 1-40 and Aβ 1-42 expression was detected by immunoblot analysis of unboiled lysates using 6E10.

Fig. 2. Hits from the yeast screen modify the toxicity of Aβ in *C. elegans* glutamatergic neurons in the same direction as in yeast. (**A**) A new animal model of Aβ toxicity. Aβ 1-42, carrying a signal sequence targeting it to the secretory compartment, was expressed in glutamatergic neurons that also expressed GFP. Neuronal death increased from 50% at day 3 to 75% at day 7, establishing that this worm model exhibits age-dependent neurodegeneration. Control genes mCherry and LacZ had no effect on Aβ-induced neurodegeneration. Measurements are relative to the number of neurons found in WT worms expressing only GFP. Bar patterns indicate distinct functional categories (crosshatches for endocytic genes). The genetic modifiers tested influenced Aβ toxicity significantly ($p < 0.05$, Student's *t*-test). *XPO1* was derived from human cDNA. For each worm (w) or human (h) gene, three transgenic lines were established and 90 worms examined for each. (**B**) Representative examples of worms scored in Fig. 2A at the third day of development. Arrowheads indicate neuronal cell bodies, marked by transgenic expression of GFP.

Fig. 3. *PICALM* protects cultured rat cortical neurons from exogenously applied Aβ oligomers. Cortical neuron cultures prepared from rat embryos at embryonic day 18 were cultured for 5 days, transduced, cultured for 13 days, and then incubated for 20 hours with 750nM of soluble Aβ oligomers prepared from synthetic peptide (*23*). Infection with a *PICALM* lentiviral construct diminished toxicity in a dose-dependent, statistically significant manner. Cell viability was assessed by both ATP content (**A**) and MAP2 positive cell counting (**B** and **C**). Data are representative of three

independent experiments and shown as mean +/- SEM (*: $p<0.05$; **: $p<0.01$, based on Dunnett's test for (A) and two-tail *t*-test for (B)).

Fig. 4. Aβ causes defects in endocytosis and receptor protein trafficking. (**A**) In a yeast strain with GFP-tagged clathrin light chain (Clc1-GFP), ssAβ 1-42 caused an increase in Clc1-GFP foci. (**B**) A halo assay, which measures secretion of the α-factor pheromone, was used to assess secretion. In the screening strain ssAβ 1-42 diminished growth but did not reduce secretion compared to the vector control. In contrast, a strain expressing α-syn, which is known to impede ER-Golgi trafficking, exhibits a strong defect in secretion. (**C**) Aβ 1-42 caused a defect in the normal trafficking of Ste3 to the vacuole. A Ste3-YFP fusion is normally trafficked to the vacuole. Aβ-expressing cells showed accumulation of Ste3-YFP in cytoplasmic foci. Co-expression of *YAP1802, INP52, and SLA1* partially restored Ste3-YFP trafficking to the vacuole. A constitutively-expressed Ste3-YFP gene was integrated in the genome of the control and screening strain. Scale bars are 5um. All images are on the same scale.

A

3 days

7 days

(Bar charts showing "Worms with 5 Glutamatergic Neurons (%)" on the y-axis, with categories: Aβ, Aβ + mCherry, Aβ + lacZ, Aβ + wPICALM, Aβ + wSYNJ1, Aβ + wSH3KBP1, Aβ + wPPP2R5C, Aβ + wADSSL1, Aβ + hXPO1, Aβ + wMAP2K4)

B

GFP | Aβ | Aβ + wPICALM | Aβ + wMAP2K4

A

% ATP content (normalized by the GFP conditions)

MOI	GFP 20	PICALM 30	GFP 20	10	PICALM 20	30
	vehicle		Aβ oligomer			

B

MAP2-positive cell count (normalized by the GFP / vehicle condition)

MOI	GFP 20	PICALM 30	GFP 20	PICALM 30
	vehicle		Aβ oligomer	

C

MAP2 / Hoechst staining

GFP / vehicle   GFP / Aβ   PICALM / Aβ

A

Clc1-YFP

Control   ssAβ 1-42 s. strain 1

B

Control   ssAβ 1-42 s. strain 1   αSyn strain

Induced

Uninduced

C

Ste3-YFP

Control   ssAβ 1-42 s. strain 1   ssAβ 1-42 *YAP1802*   ssAβ 1-42 *INP52*   ssAβ 1-42 *SLA1*